Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?
暂无分享,去创建一个
Chaya S Moskowitz | Gregory J Riely | Gregory Riely | C. Moskowitz | M. Ginsberg | Junting Zheng | D. Halpenny | S. Hayes | Helena Yu | Helena A. Yu | Junting Zheng | Michelle S Ginsberg | Darragh F Halpenny | Sara Hayes | H. Yu
[1] Jeffrey W. Clark,et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.
[2] H. Hager,et al. High resolution spiral CT for determining the malignant potential of solitary pulmonary nodules: refining and testing the test , 2011, Acta radiologica.
[3] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[4] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[5] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[6] J. Goo,et al. Imaging Characteristics of Stage I Non-Small Cell Lung Cancer on CT and FDG-PET: Relationship with Epidermal Growth Factor Receptor Protein Expression Status and Survival , 2013, Korean journal of radiology.
[7] S. Ha,et al. Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement , 2012, Cancer.
[8] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[9] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[10] K. Matsuo,et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. , 2012, Lung cancer.
[11] Grant Berges,et al. Approach to ground-glass opacification of the lung. , 2002, Seminars in ultrasound, CT, and MR.
[12] Lawrence H. Schwartz,et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. , 2013, Radiology.
[13] York Springer,et al. Ajcc Cancer Staging Manual. 7th Ed. New , 2010 .
[14] S. Ramalingam,et al. The Biology and Clinical Features of Non–small Cell Lung Cancers with EML4-ALK Translocation , 2012, Current Oncology Reports.
[15] L. Bubendorf,et al. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives , 2013, Expert review of anticancer therapy.
[16] Michelle S. Ginsberg,et al. Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features? , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.